

**Table 13.6a**  
**Immunosuppression Use for Induction, 1999 to 2008**  
**Recipients with Heart-Lung Transplants**

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
<b>Transplants</b>	51	48	27	33	29	40	35	31	31	27
<b>With Immunosuppression Info</b>	50	48	26	33	28	38	33	30	29	22
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	16.0%	29.2%	26.9%	15.2%	3.6%	13.2%	12.1%	3.3%	31.0%	13.6%
OKT3	10.0%	6.3%	0.0%	6.1%	3.6%	2.6%	3.0%	0.0%	6.9%	0.0%
Thymoglobulin	4.0%	4.2%	11.5%	3.0%	10.7%	13.2%	3.0%	6.7%	3.4%	0.0%
Zenapax	4.0%	12.5%	7.7%	15.2%	7.1%	18.4%	12.1%	16.7%	10.3%	40.9%
Simulect	0.0%	4.2%	30.8%	18.2%	17.9%	10.5%	24.2%	10.0%	24.1%	4.5%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	5.3%	9.1%	23.3%	17.2%	13.6%
<b>No Induction Drugs Recorded</b>	66.0%	47.9%	26.9%	42.4%	57.1%	42.1%	39.4%	40.0%	20.7%	27.3%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.